Extreme Thrombocytosis in Refractory ITP Post-Splenectomy With Associated Fatal Thromboembolism
Clinical Pathology, 2022 Thrombopoietin (TPO)-receptor agonists have heralded a paradigm shift in the treatment of refractory immune thrombocytopenia (ITP). Reactive thrombocytosis has been described as a secondary effect of such therapies.
Rithin Nedumannil +2 more
doaj +1 more source
Haematologica, 2014 Thrombopoietin-receptor agonists increase platelet counts by stimulating the thrombopoietin receptor. Bone marrow fibrosis has been reported in patients receiving thrombopoietin-receptor agonists.
Waleed Ghanima +6 more
doaj +1 more source
The biology of thrombopoietin and thrombopoietin receptor agonists [PDF]
International Journal of Hematology, 2013 Thrombopoietin (TPO) is the major physiological regulator of platelet production. TPO binds the TPO receptor, activates JAK and STAT pathways, thus stimulating megakaryocyte growth and platelet production. There is no "sensor" of the platelet count; rather TPO is produced in the liver at a constant rate and cleared by TPO receptors on platelets.
openaire +2 more sources
Development of thrombopoietin receptor agonists for clinical use [PDF]
Journal of Thrombosis and Haemostasis, 2009 Thrombopoietin (TPO) is an essential hematopoietic cytokine for megakaryopoiesis. In 2002, we demonstrated that pegylated-recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) increased platelet counts in patients with chronic immune thrombocytopenic purpura (ITP) in a Phase I/II clinical trial.
Y, Ikeda, Y, Miyakawa
openaire +2 more sources
Thrombopoietin Receptor Agonists in Primary Immune Thrombocytopenia [PDF]
Seminars in Hematology, 2013 Thrombopoietin (TPO) regulates thrombopoiesis through activation of TPO receptors on the megakaryocyte cell surface, resulting in increased platelet production. The TPO receptor agonists are novel treatments for patients with chronic ITP aimed at increasing platelet production through interactions with the TPO receptor on megakaryocytes.
Deborah, Siegal +2 more
openaire +2 more sources
Cost-per-responder analysis for eltrombopag and rituximab in the treatment of primary immune thrombocytopenia in Spain [PDF]
Farmacia Hospitalaria, 2020 Objective: Splenectomy, thrombopoietin receptor agonists and rituximab are the second-line treatments for steroid-resistant adult primary immune thrombocytopenia.
Eduardo Anguita +2 more
doaj +1 more source
Clinical Indications for Thrombopoietin and Thrombopoietin-Receptor Agonists [PDF]
Transfusion Medicine and Hemotherapy, 2013 Thrombocytopenia is a common hematologic disorder. Stimulation of thrombopoiesis may reduce the risk for thrombocytopenia-induced bleeding, prevent severe thrombocytopenia, and reduce the need for platelet transfusion. The key cytokine is thrombopoietin (TPO).
openaire +2 more sources
Efficacy and safety and analysis of thrombopoietin receptor agonists for the treatment of immune thrombocytopenia in adults: analysis of a systematic review and network meta-analysis of randomized controlled trials and results of real-world safety data [PDF]
Frontiers in MedicineNi Zhang, Liu Yumeng, Zhang Ni
exaly +2 more sources
Recent advances in the mechanisms and treatment of immune thrombocytopenia
EBioMedicine, 2022 Summary: Primary immune thrombocytopenia is an autoimmune disease associated with a reduced peripheral blood platelet count. The phenotype is variable with some patients suffering no bleeding whilst others have severe bleeding which may be fatal ...
Drew Provan, John W. Semple
doaj +1 more source
Medicina, 2023 Primary immune thrombocytopenia (ITP) is an acquired blood disorder that causes a reduction in circulating platelets with the potential for bleeding. The incidence of ITP is slightly higher in adults and affects more women than men until 60 years, when ...
Tomás José González-López +2 more
doaj +1 more source